Enzalutamide Soft Capsules Market - Global Forecast 2026-2032

The enzalutamide soft capsules market is emerging as a focal point for pharmaceutical executives navigating new models in oncology care and evolving policy frameworks. Senior decision-makers must anticipate how product access, supply chain strength, and real-world integration will shape strategic differentiation in advanced prostate cancer treatment.

Market Snapshot: Enzalutamide Soft Capsules Market Growth and Forecast

The Enzalutamide Soft Capsules Market demonstrates robust expansion, increasing from USD 2.72 billion in 2025 to USD 2.98 billion in 2026 and anticipated to reach USD 5.57 billion by 2032 at a CAGR of 10.78%. Growth across this market is fueled by greater adoption in both metastatic and non-metastatic prostate cancer settings. Maturing treatment protocols and a shift toward long-duration therapies create new opportunities for innovator and generic manufacturers alike. Organizations are focusing on lifecycle management, supply reliability, and payer collaboration to further accelerate commercial momentum in an environment marked by evolving clinical needs and channel dynamics.

Scope & Segmentation

Product Types: Offers a range of enzalutamide soft capsules addressing multiple strengths and packaging formats to support diverse therapeutic regimens and dispensing workflows.
Disease Stages: Covers use in both metastatic and non-metastatic prostate cancer, enabling tailored approaches for distinct patient populations throughout the care continuum.
Distribution Channels: Includes specialty pharmacy services, hospital and clinic-affiliated dispensing, and select retail pathways, supporting efficient delivery and therapy adherence.
End-User Segments: Serves large health systems, standalone oncology practices, and integrated delivery networks, each demanding dedicated access, supply logistics, and patient support solutions.
Regions Covered: Spans Americas, Europe Middle East & Africa, and Asia-Pacific, acknowledging regulatory, access, and procurement variations across established and emerging markets.
Operational Factors: Considers packaging integrity, storage requirements, refill intervals, and embedded service integration to minimize therapy interruptions and maintain product quality.

Key Takeaways

Product selection is increasingly driven by usability and workflow alignment in addition to demonstrated clinical efficacy, underscoring the value of packaging design and robust formulation.
Specialty pharmacy channels are setting new standards in patient education, support services, and side-effect management, strengthening channel partnerships as a basis for commercial differentiation.
Lifecycle management strategies and advanced distribution models are leading manufacturers to offer enhanced support programs and contract mechanisms suited to real-world oncology operations.
Regionally adapted access models must address local regulatory landscapes, procurement requirements, and distribution challenges to capture share in mature and emerging geographies.
Customized support and education, aligned with both disease stage and dispensing channel, facilitate seamless therapy integration from initiation through ongoing maintenance, supporting improved clinical outcomes and operational efficiency.

Tariff Impact: Navigating Cost and Supply Volatility

Tariff initiatives planned for 2025 are poised to disrupt sourcing and procurement for enzalutamide soft capsules, adding pressure across the supply chain. The exposure to increased costs spans active pharmaceutical ingredients, excipients, and packaging elements, impacting total materials expenditure. Adjusting sourcing strategies or modifying components to navigate these effects mandates navigation of complex regulatory pathways, particularly regarding re-validation and maintaining product stability. As a result, companies are exploring supplier diversification, building safety stock, or localizing packaging to mitigate risks. Each of these adaptations increases working capital requirements and complicates inventory management. Enterprises with a broad supplier base and strong cross-disciplinary planning capabilities will be better positioned to absorb cost volatility while maintaining supply resilience.

Methodology & Data Sources

Analysis in this report is built on triangulated research combining interviews with oncology and pharmacy stakeholders, and insights from payers, distributors, and manufacturing leaders. Secondary verification leverages regulatory databases, published clinical studies, trade documents, and annual disclosures to ensure comprehensive, actionable intelligence for procurement, clinical, and distribution strategies.

Why This Report Matters

Enables senior leadership to anticipate how evolving distribution models and policy shifts influence access strategies and competitive standing in the enzalutamide soft capsules market.
Clarifies operational risks, with recommendations for enhancing supply resilience and understanding tariff-related cost structures.
Supports strategic initiatives through granular segmentation by channel, disease stage, and geographic factors, equipping decision-makers with detailed guidance for market entry and growth.

Conclusion

Securing long-term performance in the enzalutamide soft capsules market will depend on optimizing clinical credibility, access, and supply chain excellence. Organizations prioritizing patient-centered packaging, specialist channel engagement, and supply adaptability can achieve sustained success amid ongoing shifts in oncology care delivery.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Enzalutamide Soft Capsules Market, by Dosage Strength

8.1. 120 Mg
8.2. 40 Mg
8.3. 80 Mg

9. Enzalutamide Soft Capsules Market, by Purchase Type

9.1. New Prescription
9.2. Refill

10. Enzalutamide Soft Capsules Market, by Indication

10.1. Metastatic Castration-Resistant Prostate Cancer
10.2. Metastatic Hormone-Sensitive Prostate Cancer
10.3. Non-Metastatic Castration-Resistant Prostate Cancer

11. Enzalutamide Soft Capsules Market, by Distribution Channel

11.1. Offline
11.2. Online

12. Enzalutamide Soft Capsules Market, by End User

12.1. Clinics
12.2. Hospitals
12.2.1. Private Hospital
12.2.2. Public Hospital
12.3. Specialty Centers

13. Enzalutamide Soft Capsules Market, by Region

13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific

14. Enzalutamide Soft Capsules Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Enzalutamide Soft Capsules Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. United States Enzalutamide Soft Capsules Market
17. China Enzalutamide Soft Capsules Market

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbott Healthcare Private Limited
18.6. Adley Formulations Private Limited
18.7. Alizyme Healthcare Limited
18.8. Aprazer Healthcare Private Limited
18.9. Astellas Pharma Inc.
18.10. BDR Pharmaceuticals International Private Limited
18.11. Cipla Limited
18.12. Dr. Reddy’s Laboratories Limited
18.13. Glenmark Pharmaceuticals Limited
18.14. Halsted Pharma Private Limited
18.15. Hetero Healthcare Limited
18.16. Intas Pharmaceuticals Limited
18.17. K. K. Pharma Solutions Private Limited
18.18. Medisus Pharma Private Limited
18.19. Pfizer Inc.
18.20. RPG Life Sciences Limited
18.21. Rutika Lifescience Private Limited
18.22. Samarth Life Sciences Private Limited
18.23. Sun Pharmaceutical Industries Limited
18.24. Zydus Lifesciences Limited

List of Figures

FIGURE 1. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 120 MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 40 MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY 80 MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NEW PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NEW PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NEW PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REFILL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 55. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 56. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 57. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 58. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 59. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 60. AMERICAS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 61. NORTH AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. NORTH AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 63. NORTH AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 64. NORTH AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 65. NORTH AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 66. NORTH AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 68. LATIN AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. LATIN AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 70. LATIN AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 71. LATIN AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 72. LATIN AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 73. LATIN AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 74. LATIN AMERICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 82. EUROPE ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. EUROPE ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 84. EUROPE ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 85. EUROPE ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 86. EUROPE ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 87. EUROPE ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 88. EUROPE ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 89. MIDDLE EAST ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. MIDDLE EAST ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 91. MIDDLE EAST ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 92. MIDDLE EAST ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 93. MIDDLE EAST ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 94. MIDDLE EAST ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. MIDDLE EAST ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 96. AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 98. AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 99. AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 100. AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 101. AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. AFRICA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. ASEAN ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. ASEAN ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 113. ASEAN ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 114. ASEAN ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 115. ASEAN ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. ASEAN ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 117. ASEAN ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 118. GCC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GCC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 120. GCC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 121. GCC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 122. GCC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. GCC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. GCC ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 125. EUROPEAN UNION ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. EUROPEAN UNION ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 127. EUROPEAN UNION ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 129. EUROPEAN UNION ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 132. BRICS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. BRICS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 134. BRICS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 135. BRICS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 136. BRICS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. BRICS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. BRICS ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 139. G7 ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. G7 ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 141. G7 ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 142. G7 ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 143. G7 ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 144. G7 ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. G7 ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 146. NATO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. NATO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 148. NATO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 149. NATO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 150. NATO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. NATO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. NATO ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 155. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 156. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 157. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 158. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 159. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. UNITED STATES ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 161. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 162. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 163. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY PURCHASE TYPE, 2018-2032 (USD MILLION)
TABLE 164. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 165. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. CHINA ENZALUTAMIDE SOFT CAPSULES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Enzalutamide Soft Capsules market report include:

Abbott Healthcare Private Limited
Adley Formulations Private Limited
Alizyme Healthcare Limited
Aprazer Healthcare Private Limited
Astellas Pharma Inc.
BDR Pharmaceuticals International Private Limited
Cipla Limited
Dr. Reddy’s Laboratories Limited
Glenmark Pharmaceuticals Limited
Halsted Pharma Private Limited
Hetero Healthcare Limited
Intas Pharmaceuticals Limited
K. K. Pharma Solutions Private Limited
Medisus Pharma Private Limited
Pfizer Inc.
RPG Life Sciences Limited
Rutika Lifescience Private Limited
Samarth Life Sciences Private Limited
Sun Pharmaceutical Industries Limited
Zydus Lifesciences Limited

Table Information

Report Attribute	Details
No. of Pages	185
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 2.98 Billion
Forecasted Market Value ( USD ) by 2032	$ 5.57 Billion
Compound Annual Growth Rate	10.7%
Regions Covered	Global
No. of Companies Mentioned	21

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3513EUR$3,939USD£3,047GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3789EUR$4,249USD£3,286GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5136EUR$5,759USD£4,454GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6215EUR$6,969USD£5,390GBP

Market Snapshot: Enzalutamide Soft Capsules Market Growth and Forecast

Scope & Segmentation

Key Takeaways

Tariff Impact: Navigating Cost and Supply Volatility

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Enzalutamide Drugs Market - Global Forecast 2026-2032

Enzalutamide Tablets Market - Global Forecast 2026-2032

Non-metastatic Prostate Cancer Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

Androgen Receptor Inhibitor Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

Prostate Cancer Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type